HPV Vaccine Administration Guidelines
The HPV vaccine (Gardasil 9) should be administered intramuscularly in the deltoid muscle, with the dosing schedule determined by age at initiation: 2 doses (0,6-12 months) for those starting before age 15, and 3 doses (0,1-2,6 months) for those starting at age 15 or older. 1, 2
Route and Site of Administration
The vaccine is given as an intramuscular injection in the arm muscle (deltoid) 2. This is the standard route for all age groups and both sexes.
Age-Based Dosing Schedules
Ages 9-14 Years: 2-Dose Schedule
- Dose 1: Initial shot
- Dose 2: Given 6-12 months after the first dose
- Critical caveat: If the second dose is given earlier than 5 months after the first shot, a third dose must be administered at least 4 months after the second dose 2
Ages 15-26 Years: 3-Dose Schedule
Ages 27-45 Years: Shared Decision-Making
Catch-up vaccination is not routinely recommended for all adults over 26 years. Instead, use shared clinical decision-making for select individuals aged 27-45 who are not adequately vaccinated 1. The vaccine is not licensed for use in adults over 45 years 1.
Consider vaccination in this age group only for:
- Individuals with new sexual partners (highest risk for new HPV acquisition)
- Those not in long-term mutually monogamous relationships
- Individuals who understand that vaccine effectiveness is substantially lower due to likely prior HPV exposure 1
Special Populations
Immunocompromised Individuals
Always use a 3-dose schedule (0,1-2,6 months) regardless of age at initiation, including those with HIV infection or taking immunosuppressive medications 1. This is a critical exception to the 2-dose schedule for younger adolescents.
Pregnancy
- Delay vaccination until after pregnancy 3
- No pregnancy testing is required before vaccination 1
- If a patient becomes pregnant during the vaccine series, delay remaining doses until after pregnancy
- Breastfeeding is not a contraindication to vaccination 3
Post-Administration Monitoring
Observe patients for 15 minutes after vaccination due to syncope risk 2. This is particularly important in adolescents. Have patients sit or lie down during this observation period, as fainting can lead to falls and injury.
Contraindications
Do not administer if the patient has:
- Severe allergic reaction to a previous HPV vaccine dose
- Severe yeast allergy
- Allergy to amorphous aluminum hydroxyphosphate sulfate or polysorbate 80
- Fever over 100°F (37.8°C) - defer vaccination 2
Co-Administration with Other Vaccines
Gardasil 9 can be given simultaneously with:
- Menactra (meningococcal vaccine)
- Adacel (Tdap vaccine)
Note: Expect increased injection site swelling when co-administered with these vaccines 2.
Key Clinical Pitfalls to Avoid
- Don't use a 2-dose schedule for immunocompromised patients - they always need 3 doses regardless of age
- Don't forget the minimum 5-month interval for the 2-dose schedule - shorter intervals require a third dose
- Don't perform pre-vaccination HPV or Pap testing - it's not recommended and doesn't determine vaccine appropriateness 1
- Don't skip cervical cancer screening - vaccination does not eliminate the need for routine screening 2
- Don't assume the vaccine treats existing HPV infection - it is purely prophylactic and prevents new infections only 1
Routine Vaccination Timing
Optimal timing is age 11-12 years (can start as early as age 9), before sexual debut when the vaccine provides maximum benefit 1. Catch-up vaccination is recommended for all persons through age 26 who are not adequately vaccinated 1.